Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | USP1 | O94782 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22719293 | 0.85 | MGLL (0.43) | MGLLGPR119TACR1PPARDMMP13 | |
| SCHEMBL3661148 | 0.82 | GPR119 (0.44) | MGLLGPR119TACR1MMP13ADAM17 | |
| SCHEMBL209368 | 0.81 | PPARD (0.59) | MGLLGPR119PPARD | |
| SCHEMBL14155585 | 0.81 | NAMPT (0.46) | MGLL | |
| SCHEMBL14357682 | 0.80 | KDM1A (0.48) | TACR1OPRD1OPRK1 | |
| SCHEMBL21765280 | 0.80 | MGLL (0.46) | MGLLGPR119TACR1PPARDOPRD1 | |
| SCHEMBL24485248 | 0.79 | MEN1 (0.52) | MGLLTACR1OPRD1OPRK1 | |
| SCHEMBL18321733 | 0.79 | RORC (0.45) | GPR119TACR1OPRD1OPRK1MMP13 | |
| SCHEMBL25133820 | 0.79 | GPR119 (0.52) | GPR119TACR1OPRD1OPRK1 | |
| SCHEMBL26081086 | 0.79 | IDH1 (0.43) | GPR119TACR1IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | MGLL 2002/4885GPR119 721/4885TACR1 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.